HC Wainwright Comments on FibroGen FY2024 Earnings

FibroGen, Inc. (NASDAQ:FGEN) – Research analysts at HC Wainwright issued their FY2024 earnings per share (EPS) estimates for FibroGen in a report issued on Tuesday, December 17th. HC Wainwright analyst M. Keller anticipates that the biopharmaceutical company will post earnings of ($0.74) per share for the year. HC Wainwright has a “Strong-Buy” rating on the stock. The consensus estimate for FibroGen’s current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for FibroGen’s Q4 2024 earnings at ($0.08) EPS and FY2025 earnings at ($0.53) EPS.

Other analysts have also recently issued research reports about the company. StockNews.com initiated coverage on FibroGen in a research report on Monday. They issued a “hold” rating for the company. William Blair reissued a “market perform” rating on shares of FibroGen in a research note on Wednesday, November 13th.

FibroGen Trading Up 3.3 %

FGEN stock opened at $0.35 on Thursday. The firm has a market cap of $35.64 million, a PE ratio of -0.29 and a beta of 0.82. FibroGen has a 1 year low of $0.18 and a 1 year high of $2.93. The company has a fifty day simple moving average of $0.35 and a 200 day simple moving average of $0.57.

FibroGen (NASDAQ:FGEN) last issued its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.21. The business had revenue of $46.33 million for the quarter, compared to the consensus estimate of $34.00 million. During the same period in the previous year, the business posted ($0.52) EPS.

Hedge Funds Weigh In On FibroGen

A number of institutional investors have recently made changes to their positions in FGEN. Geode Capital Management LLC grew its holdings in FibroGen by 3.1% in the 3rd quarter. Geode Capital Management LLC now owns 1,083,521 shares of the biopharmaceutical company’s stock valued at $433,000 after buying an additional 32,884 shares during the last quarter. Sei Investments Co. boosted its position in shares of FibroGen by 38.4% in the second quarter. Sei Investments Co. now owns 149,342 shares of the biopharmaceutical company’s stock valued at $133,000 after acquiring an additional 41,442 shares during the period. Point72 DIFC Ltd grew its stake in shares of FibroGen by 734.2% in the second quarter. Point72 DIFC Ltd now owns 52,254 shares of the biopharmaceutical company’s stock worth $47,000 after acquiring an additional 45,990 shares during the last quarter. Doheny Asset Management CA bought a new position in FibroGen during the second quarter worth $48,000. Finally, FMR LLC increased its position in FibroGen by 21.8% during the third quarter. FMR LLC now owns 383,258 shares of the biopharmaceutical company’s stock worth $153,000 after acquiring an additional 68,569 shares during the period. 72.71% of the stock is currently owned by institutional investors.

About FibroGen

FibroGen, Inc, a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Pamrevlumab, a human monoclonal antibody targeting connective tissue growth factor that is in Phase III clinical development for the treatment of locally advanced pancreatic cancer; and Roxadustat, an oral small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes.